Vertex set to acquire Crinetics Pharmaceuticals, adding endocrinology assets with significant commercial and pipeline potential

Vertex Pharmaceuticals and Crinetics Pharmaceuticals have entered into a definitive agreement under which Vertex will acquire Crinetics at eighty-five dollars per share in cash, placing the total equity value of the transaction at approximately ten billion dollars, or around eight-point-eight billion dollars net of estimated cash acquired. Both companies’ boards of directors gave unanimous backing to the deal, which is expected to close in the third quarter of 2026.

Crinetics’ marketed medicine PALSONIFY (paltusotine) received US Food and Drug Administration approval in September 2025 and has since also been cleared by the European Medicines Agency, with reviews ongoing in additional markets. It stands as the first and only once-daily oral therapy for adults with acromegaly, a rare and debilitating condition in which a pituitary tumour drives excess growth hormone production, affecting an estimated 20,000 diagnosed individuals in the US. The medicine delivers rapid disease control and normalisation of key disease markers across both previously treated and untreated patient groups. Since its commercial launch, PALSONIFY has built encouraging early momentum, with strong demand across all patient segments, an expanding prescriber base, and growing reimbursement coverage all pointing to its potential to reshape how acromegaly is treated.

Atumelnant, Crinetics’ most advanced pipeline candidate, is a once-daily oral adrenocorticotropic hormone receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia. The classic form of the disease, which represents the most severe variant and affects around 17,000 addressable patients in the US, is a rare chronic genetic condition of the adrenal glands carrying significant unmet need. The condition is characterised by impaired cortisol production and, in most cases, excess androgen levels, both of which drive a range of serious health consequences. Phase 2 data showed that patients on atumelnant were able to bring excess androgen levels close to normal while using physiologic replacement doses of glucocorticoids, a therapeutic profile that positions the medicine as a potential leading treatment for those struggling with congenital adrenal hyperplasia. Atumelnant has been generally well tolerated to date, with no treatment-related severe or serious adverse events recorded.

“Crinetics is an excellent strategic fit for Vertex, with its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines that could deliver transformative benefit to patients,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “We believe Vertex can build on the strong momentum of the PALSONIFY launch by applying our experience in commercializing medicines for rare genetic diseases. We are also excited by the significant potential of atumelnant to transform the treatment landscape for CAH, setting a new standard of care where patients do not have to choose between managing their excess adrenal androgens and enduring the side effects of high-dose steroids.”

“We look forward to working with the talented Crinetics team to rapidly advance their pipeline of medicines for patients living with serious, rare endocrine disorders. Together, these potential blockbuster assets build on our core CF business, ongoing launches and internal innovation portfolio, adding to our growth outlook and driving value for patients and shareholders,” she continued.

“Nearly 18 years ago, we founded Crinetics with a clear goal of transforming the lives of patients living with endocrine-related diseases. Today marks a historic milestone as we embark on this next chapter with Vertex,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics Pharmaceuticals. “This partnership is anchored by a mutual commitment to science and a shared vision for delivering innovative treatments to patient communities that have long been underserved. Vertex’s global infrastructure and commercial footprint will serve to amplify the reach of our science and allow us to maximize the impact of PALSONIFY, atumelnant and our pipeline. I want to extend my deepest gratitude for the relentless dedication, brilliance and passion of our extraordinary employees, who have worked tirelessly to bring our scientific vision to life, as well as the clinical partners and patient communities who have championed our mission from the very beginning.”

---

---

Related Topics and Keywords

crinetics, Crinetics Pharmaceuticals, vertex